Gainesville, FL – June 29, 2020 – Evren Technologies announced today that Mr. Richard Ferrari, Co-Founder of De Novo Ventures, has joined the board of directors of Evren.
De Novo Ventures has $650 million under management and is one of the premier firms dedicated to medical devices and biotechnology. Mr. Ferrari has raised over a billion dollars for companies he has directly influenced and participated in approximately $1.5 billion in acquisition events. Additionally, he has been a successful CEO of two publicly traded medical technology companies including Cardiovascular Imaging Systems, the first and leading developer of ultrasound imaging catheters which was eventually acquired for $125 million by Boston Scientific, and CardioThoracic Systems (CTS), the market leader in disposable instruments and systems for performing minimally invasive beating heart bypass surgery, which was acquired by Guidant for $350 million. Mr. Ferrari is the recipient of the Mallinckrodt Award for Excellence in Medicine and has been a finalist for the Entrepreneur of the Year Award. He holds a BS degree from Ashland University and an MBA from the University of South Florida.
“We are fortunate and honored to have Mr. Ferrari on our board of directors,” said Blythe Karow, President & CEO of Evren. “I know we will benefit greatly from his knowledge and experience.
About Evren Technologies
Evren Technologies is a development stage bioelectronic medicine company at the forefront of two of the most rapidly-growing spaces in the medical device industry: Vagal Nerve Stimulation (VNS), and wearable tech. We are bringing cutting-edge VNS technology to a user-friendly and intelligent hardware and software platform that is easy to use and personalized. Our initial product - the Phoenix™ - delivers transcutaneous auricular vagal nerve stimulation in a discreet earbud design for the treatment of Post-Traumatic Stress Disorder (PTSD).